United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease

• United Therapeutics Corp (NASDAQ: UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with chronic obstructive pulmonary disease.

• The company terminated the study based on a recommendation of the study's independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC.

• The company will review the study's available data and plan to share the results with the scientific community.

• According to clinicaltrials.gov, the trial was expected to conclude in 2024.

• In its Q2 earnings release, United Therapeutics disclosed it decided to trigger a pre-specified transition and convert the PERFECT study from a crossover study into a single treatment period of 12 weeks.

• Price Action: UTHR shares are down 3.44% at $209.42 on the last check Tuesday.

See more from Benzinga

• Spectrum Plunges After FDA Casts Doubts On Its Lung Cancer Candidate

• Thermo Fisher Invests $160M to Expand Bioproduction Capacity

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.